Very informative video. It will help me support my father dealing with CML. Thank you very much.

So clear...... thank you so much

Brilliant 👏 👏 👏 Thanks so much

Thank you so much Doctor. Can you make a video on microscopic identification of malignant hematopoietic cells in acute and chronic myeloid and lymphoid leukemias based on unique identifiable microscopic features and also if possible a video on the atlas of blood cells.

Thank u Sir 🙌🏾

Thank you for sharing. 5th year

when this video appeared in April 2020 I was recovering from a Micro Perfed Colon a side effect of Bosulif,My PCR had risen to 0.17 while taking CBD Gummies for inflammation, I was prescribed dasatinib but told to wait for the next blood test to resume treatment. in the interim I went to resupply my CBD Gummies,but due to supply was offered 500 Mg Tincture, I got 4 vials and consumed 1 per day and then it was time for my next blood draw, and the Nurse called and said "your results are good"

What to do if patient has taken every generation of TKI without long term sustainable effectiveness? What if a patients body/blood has been resistant to all these generations of tki going on about 6 years?

Amazing video! Thank you doctor! I was reading in Harrison this subject and it said that 50-60% of patients in development countries are diagnosed with systematic blood tests and they usually have no symptoms other than maybe fatigue, because of the anemia, so my question is: in the blood test what makes you suspect of CML? Is high wbc >100,000/uL and anemia (like you mentioned in the video) what arises the suspicion of CML?

Are there any studies using Metabolic Therapy for CML or AML? I started #Carnivore and my mutation load is going DOWN?

Hai sir am from karnataka, one of my close few days back diagnoised from CML what we have to next... He was so depressed..... Pls help him

DR Kim; I just wanted to inform you that I had a PCR and it was 0.17

Hello sir. Is it compulsory to do bone marrow karyotyping in case of CML. Or diagnosis can be done by abl Bcr test . And treatment can be started soon after ?

Is Anyone here who in treatment free remission from cml.

I'm a CML patient

How can one beat this if you don’t have health insurance or income source to pay for the pills and medical bills?

Hello sir, my father also suffering from CML, taking imatinb 400 for 1 year.. Now he is feeling more pain in bones ( shoulder, back, thies), is there any medicine to decrease the bone pain?

Thank you sir.. my husband is also a CML patient from the Philipines for 18 years.. he is taking sprycel

For the 3rd line therapy, asciminib has shown more effective than bosutinib. Updated results from the phase 3 ASCEMBL trial confirmed the superior efficacy and tolerability of asciminib over bosutinib in patients with chronic myeloid leukemia in chronic phase after treatment with two or more tyrosine kinase inhibitors. The updated data, which were presented at the 2022 ASCO Annual Meeting, also showed that a higher proportion of patients assigned to asciminib achieved a BCR-ABL1IS ≤ 1%, which was associated with better survival outcomes. In the ASCEMBL study, patients with CML in chronic phase were randomly assigned to twice-daily asciminib (40 mg), a BCL-ABL1 inhibitor targeting the ABL Myristoyl Pocket, or to once-daily bosutinib (500 mg). In total, 157 patients were assigned to asciminib, and 76 patients were assigned to bosutinib. With a median follow-up of 2.3 years, the updated data presented the major molecular response rate at 96 weeks, a key secondary endpoint of the study. At the time of reporting, 53.5% (n = 84) of patients in the asciminib arm and 19.7% (n = 15) of patients in the bosutinib arm continued to receive treatment. In both arms, lack of efficacy served as the most common reason for treatment cessation (ascimib, 24.2%; bosutinib, 35.5%). The major molecular response rate in the intent-to-treat population favored the asciminib arm (37.5% vs 15.8%). When the researchers adjusted for major cytogenetic response status at baseline (Philadelphia chromosome-positive metaphases ≤ 35%), which served as a stratifying factor, they observed a difference of 21.7% (95% CI, 10.5-33; 2-sided P = .001). A greater percentage of patients in the asciminib arm achieved BCR-ABL1IS ≤ 1% at 96 weeks (45.1% vs19.4%). The probability of maintaining major molecular response for 72 weeks or longer was 96.7% (95% CI, 87.4-99.2) for patients assigned asciminib and 92.9% (95% CI, 59.1-99) for patients assigned bosutinib. The probability of maintaining BCR-ABL1IS ≤ 1% for 72 weeks or greater were 94.6% (95% CI, 86.2-97.9) for asciminib and 95% (95% CI, 69.5-99.3) for bosutinib. The median duration of response favored treatment with asciminib (103.1 weeks vs 30.5 weeks), and although patients assigned asciminib had longer intervals on treatment, they experienced fewer toxicities. Compared with bosutinib, patients assigned to asciminib had fewer adverse events (any grade, 91% vs 97.4%; grade ≥ 3, 56.4% vs 68.4%) and adverse events leading to discontinuation (any grade, 7.7% vs 26.3%; grade ≥ 3, 7.7% vs 19.7%). The most observed grade 3 or higher adverse events were thrombocytopenia (asciminib vs bosutinib, 22.4% vs 9.2%), neutropenia (18.6% vs 14.5%), diarrhea (0% vs 10.5%), and increased alanine aminotransferase (0.6% vs 14.5%). meetings.asco.org/abstracts-presentations/208188

I took Tasigna for my CML and it almost killed me, my back, legs, feet and toes hurt all the time.

I'm a CML patient also

I have cml

My sister is suffering from CML from 2019. And she is using imtanib 400 mg. Is it curable

the side effects will kill the patient! I would NEVER agree to this type of treatment!

Is cml is curable sir???

Thank you Dr Omoh on KZfaq for being the reason why am smiling today, your herbal supplements sir are indeed very effective. Keep saving lives Sir,,,

Hi doctor I am 74 yrs. Earlier I was taking dasatinib but all the times side effects. Now I am taking Imatinib 400 but blood counts decrease every month I.e. below the normal parameters. Should I stop taking medicine?

Mere papa k cml aaj pata chala . Koi meri plz help karo mai kya karu . Mere papa k initial stage hai ?? Mere papa thik ho jaenge? Life expectancy kya hai ??? Kya yr curable hai??

Has anyone had plastic surgery after cml diagnosis

Hello sir.. Am from India.. Am diagnosed with CML chronic phase 7 years back.. Am on nilotinib..Am fine now

I m also cml patient....and i taken tasegna.... please tell me that i take this medicine for how long....is this cure...

I am a CML patient since 2019 and intolerant to Imatinib, Dasatinib, Nilotinib and Bosutinib. Having chest bone pain since 2019. Now dr suggested me to take Drug named Asciminib which they are importing from Switzerland. I don't know how it gonna respond to my body. When can I stop having drugs??

Sir mere husband ko CML hai 2018 se..nilotinib kha rahe h... Last report 0.30 hai.. Is this cureable..?????sir

Sir I am cml patient and taking imatinib. Can I take corona vaccine. I am from india

I'm cml patient too can I take the corona vaccine too?

Dear DR Kim; If you are a man of Science why have you not contacted me for Intelligent conversation or further investigation. Perhaps ,Possibly you are a business man first a man of science 2nd and a DR last. please correct me if I have mischaracterized

The FDA has approved asciminib to treat patients with chronic Philadelphia chromosome-positive chronic myeloid leukemia (CML). A release from the manufacturer described asciminib as “the first FDA-approved CML treatment that works by binding to the ABL myristoyl pocket.” The approval is for patients treated with two or more tyrosine kinase inhibitors and those with the T315I mutation, according to the release. The approval follows results from the phase 3 ASCEMBL trial, which compared patients treated with either 40 mg asciminib twice daily or 500 mg of bosutinib once daily, and the phase 1 NCT02081378 study that included patients with the mutation. The primary efficacy outcome of the ASCEMBL trial was major molecular response (MMR) at 24 weeks, with an MMR rate of 25% (95% CI: 13-33) in the asciminib arm compared to 13% (95% CI: 6.5-23; p=0.029) in the bosutinib group. The release noted that with a median duration of follow-up of 20 months, the trial had not reached a median MMR.